title: Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature.
abstract: OBJECTIVE
  Anaplastic thyroid cancer (ATC) is a rare and deadly malignancy. There is a need to speed up and support clinical research. This review article focuses on the new molecules that have been developed for the treatment of this aggressive tumor.
  
  
  RESULTS
  Improvement in the knowledge of pathogenesis and genetics of ATC led to the development of a variety of new molecules that may be used to treat this disease. In summary, these molecules are proteasome inhibitors, Aurora kinase inhibitors, vascular targeting agents, and gene therapies. All these molecules demonstrated a potentially therapeutic activity in metastatic ATC. To date, the largest prospective randomized multicenter, open-label, trial was conducted with combretastatin-A4.
  
  
  CONCLUSIONS
  More efficient drugs need to be developed through multinational efforts.
authors.affiliation: Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Roberta
authors.initials: R
authors.lastname: Granata
authors.forename: Laura
authors.initials: L
authors.lastname: Locati
authors.forename: Lisa
authors.initials: L
authors.lastname: Licitra
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D006801:Humans; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic; D013267:Stilbenes / Q000008:administration & dosage; D065646:Thyroid Carcinoma, Anaplastic; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D013267:Stilbenes; C058728:fosbretabulin